Literature DB >> 1898247

HLA-DR expression on the microvasculature of portal tracts in idiopathic portal hypertension. Immunohistochemical characteristics and relation to portal phlebosclerosis.

T Terada1, Y Nakanuma, H Obata.   

Abstract

We recently reported that HLA-DR antigen was expressed on the microvasculature of portal tracts more frequently in idiopathic portal hypertension (IPH) than in normal livers or in other hepatic diseases, and that this HLA-DR expression may be involved in the development of the portal venopathy characteristic of IPH. The present study was performed to evaluate the relationship between the HLA-DR expression and portal tract lesions, as well as to investigate the immunohistochemical characteristics of the HLA-DR-positive microvasculature using liver wedge biopsy specimens obtained from 32 patients with IPH. According to the degree of phlebosclerosis of the portal veins, the portal tracts were divided into three groups: mild, moderate, and severe. The microvasculature in portal tracts was positive for HLA-DR in 21 (66%) of the 32 specimens and in 133 (44%) of 302 portal tracts. In the 21 specimens, there was no significant difference in the prevalence of HLA-DR-positive microvasculature among the three groups: it occurred in 57 (66%) of 86 portal tracts in the mild group, 53 (61%) of 87 portal tracts in the moderate group, and 23 (49%) of 47 portal tracts in the severe group. The HLA-DR-positive microvasculature was positive for type IV collagen and receptors of Ulex europaeus lectin I, suggesting that HLA-DR-positive microvessels are blood vessels. These findings suggest that HLA-DR antigen is already expressed on portal microvessels in the incipient stage of IPH, and that HLA-DR expression persists during the progression of portal phlebosclerosis. The HLA-DR expression may be an initiating factor leading to immunologic assault on portal microvessels in IPH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898247

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

1.  Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.

Authors:  Y Sato; X S Ren; K Harada; M Sasaki; H Morikawa; S Shiomi; M Honda; S Kaneko; Y Nakanuma
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 2.  The current clinical aspects of idiopathic portal hypertension.

Authors:  Tomohiro Tanaka; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

Review 3.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

4.  Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.

Authors:  Shiv Kumar Sarin; Ashish Kumar; Yogesh Kumar Chawla; Sanjay Saran Baijal; Radha Krishna Dhiman; Wasim Jafri; Laurentius A Lesmana; Debendranath Guha Mazumder; Masao Omata; Huma Qureshi; Rizvi Moattar Raza; Peush Sahni; Puja Sakhuja; Mohammad Salih; Amal Santra; Barjesh Chander Sharma; Praveen Sharma; Gamal Shiha; Jose Sollano
Journal:  Hepatol Int       Date:  2007-09-11       Impact factor: 6.047

5.  Monolobar hepatobiliary fibropolycystic disease.

Authors:  Tadashi Terada; Toshiaki Moriki
Journal:  Pathol Oncol Res       Date:  2010-05-30       Impact factor: 3.201

6.  Idiopathic portal hypertension associated with high serum titer of autoantibodies and liver dysfunction.

Authors:  K Mori; E Ishimura; H Goto; S Shoji; S Seki; T Yamashita; K Wakasa; Y Nishizawa; H Morii
Journal:  J Gastroenterol       Date:  1996-02       Impact factor: 7.527

7.  A case of small well-differentiated hepatocellular carcinoma with marked lymphocytic infiltrate.

Authors:  Tomohiro Iwasaki; Aki Kubota; Makoto Suzuki; Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

8.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.